Zacks Small Cap Boosts Earnings Estimates for Edesa Biotech

Edesa Biotech, Inc. (NASDAQ:EDSA) – Stock analysts at Zacks Small Cap increased their Q2 2025 earnings estimates for Edesa Biotech in a research report issued on Monday, March 3rd. Zacks Small Cap analyst D. Bautz now forecasts that the company will post earnings per share of ($0.17) for the quarter, up from their previous forecast of ($0.38). The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.75) per share. Zacks Small Cap also issued estimates for Edesa Biotech’s Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.02) EPS, FY2026 earnings at ($0.56) EPS and FY2027 earnings at ($0.45) EPS.

Edesa Biotech Stock Performance

NASDAQ EDSA opened at $2.27 on Wednesday. The firm has a 50 day simple moving average of $2.01 and a 200-day simple moving average of $2.88. Edesa Biotech has a one year low of $1.55 and a one year high of $5.59. The firm has a market cap of $15.74 million, a price-to-earnings ratio of -1.21 and a beta of 0.77.

Edesa Biotech (NASDAQ:EDSA) last announced its earnings results on Friday, February 14th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.17). During the same period in the prior year, the firm earned ($0.54) EPS.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Edesa Biotech stock. Citadel Advisors LLC acquired a new position in shares of Edesa Biotech, Inc. (NASDAQ:EDSA) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 40,944 shares of the company’s stock, valued at approximately $70,000. Citadel Advisors LLC owned approximately 1.18% of Edesa Biotech at the end of the most recent quarter. Institutional investors own 5.50% of the company’s stock.

About Edesa Biotech

Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.